Literature DB >> 6277260

Immune responses to varicella-zoster in the aged.

B L Burke, R W Steele, O W Beard, J S Wood, T D Cain, D J Marmer.   

Abstract

Skin test reactivity and in vitro lymphocyte stimulation responses to varicella-zoster (VZ) were examined in a large normal population ranging in age from 6 months to 93 years. Warning of cellular immunity, as examined by skin delayed hypersensitivity, began at age 40 years. Skin test responses to phytohemagglutinin, however, remained positive into the eighth decade of life. In vitro lymphocyte stimulation responses to VZ were usually positive (stimulation index greater than or equal to 2.5) until age 60 years, after which time levels, as observed with nonimmune individuals, were often demonstrated. Antibody levels, as measured by fluorescent antibody to membrane antigen, remained positive into the ninth and tenth decades of life. This was especially so with a history of reactivation (zoster) VZ infections, while skin test and in vitro responses were rarely positive in those individuals. This cellular, as contrasted with humoral, immunity decreases with advancing age, which may account for a propensity to reactivation of VZ virus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277260

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  75 in total

1.  Case-control study of the effect of mechanical trauma on the risk of herpes zoster.

Authors:  S L Thomas; J G Wheeler; Andrew J Hall
Journal:  BMJ       Date:  2004-01-23

2.  The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster.

Authors:  G P Garnett; B T Grenfell
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

Review 3.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

4.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

5.  Can herpes zoster be prevented?

Authors:  M J Levin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

Review 6.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Jesse Dewane; Joshua Walker; Wayne Gray; Ilhem Messaoudi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Chickenpox at Ninety Four: A Case for Extending the Use of Varicella Vaccine in the UK.

Authors:  Justin Bendig; Fiona Sindall
Journal:  Case Rep Med       Date:  2010-06-09

9.  A case of optic neuritis complicating herpes zoster ophthalmicus in a child.

Authors:  Seong Min Hong; Yun Sik Yang
Journal:  Korean J Ophthalmol       Date:  2010-04-06

10.  Serology, clinical manifestations and treatment of brucellosis in different age groups.

Authors:  J D Colmenero; J M Reguera; F P Cabrera; J M Cisneros; D L Orjuela; J Fernández-Crehuet
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.